In daily clinical practice when decisions are made about the value of exercise testing in patients with cardiovascular disease, the focus is inevitably on measures that reflect the state of the coronary arterial circulation, owing to the potential requirement for coronary angiography and revascularization. Hence, exercise capacity is typically brought into play in the context in which ischemic responses are interpreted: ischemia in the setting of poor exercise capacity means high risk, whereas in the setting of good exercise capacity it has little prognostic impact [1] . Conversely, although clinicians have long been aware that high levels of exercise capacity are associated with a better prognosis [2] , the widespread tendency to ignore exercise capacity in clinical management seems to be linked to a general uncertainty about the therapeutic implications of exercise capacity.
Exercise capacity can be of therapeutic value in two ways. As a non-modifiable indicator of risk, it can direct us to higher-risk patients who need a more intensified management: the benefits of coronary artery bypass graft (CABG) seem to be confined to those coronary artery disease (CAD) patients with impaired exercise capacity, even among patients with left ventricular systolic dysfunction [3] ; and, in patients referred for rehabilitation after myocardial infarction, CABG or chronic ischemic heart disease, peak oxygen consumption (peak VO 2 ) is selected as the most important independent predictor of both cardiac and all-cause deaths, adjusted for confounding factors such as age, diabetes, continuing smoking, exertional hypotension, ST-segment depression, exercise-induced arrhythmias and various cardioactive drugs [4, 5] . As a modifiable risk factor, poor exercise capacity can specifically indicate the need to improve functional tolerance through exercise training. Even modest gains in cardiorespiratory fitness (þ 1 ml/kg per min of peak VO 2 ) can translate into a substantial lowering of cardiac mortality (9-10%) in both female and male CAD patients [4, 5] and, in selected stable CAD patients with mild exercise-induced symptoms and preserved left ventricular systolic function, a 12-month program of exercise training is associated with a significant increase in peak VO 2 and results in superior event-free survival compared to percutaneous coronary intervention [6] .
Accurate assessment of exercise capacity is, then, crucial [7] . Although exercise capacity estimated on the basis of the speed and grade of the treadmill is the most commonly used clinical measure of exercise tolerance, peak VO 2 derived from symptom-limited cardiopulmonary exercise testing (CPET) is known to be a more accurate and reproducible measure of exercise tolerance, as well as a more robust predictor of outcomes [8] . In addition, since virtually all of the factors that contribute to the onset of symptoms during exercise may be reliably measured or inferred from the results of CPET, all the available treatment options to counteract disability can more properly be prescribed and managed according to CPET findings. It follows that CPET indications should be extended to every clinical setting where the objective definition of exercise capacity has clinical implications.
A statement on cardiopulmonary exercise testing in chronic heart failure (CHF) due to left ventricular dysfunction, by the Gruppo Italiano di Cardiologia Riabilitativa (GICR) and endorsed by the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology, has recently been published in the European Journal of Cardiovascular Prevention and Rehabilitation. The document is split into three sections, accessible in the April, June and August issues of this year [9] [10] [11] . This exhaustive and collaborative work provides recommendations on clinical indications, issues of standardization and interpretative strategies of CPET in CHF, based on contemporary scientific knowledge and technical advances, and constitutes a platform for a broadened use of CPET, beyond the traditional CHF indication. Since peak VO 2 is one of the most potent prognostic variables ever discovered and almost all patient management decisions are driven by the clinician's assessment of the patient's prognosis, the next major priority should be the design of large-scale randomized trials to determine whether the implementation of CPET in cardiac rehabilitation and prevention may lead to an improvement in outcome discrimination.
